Aura Biosciences (AURA) risk factors, FY2025 10-K

Risks Related to Our Financial Position, and Additional Capital Needs

1. 01We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future, which raises a risk regarding our ability to continue as a going concern
2. 02attracting, hiring, and retaining qualified personnel98% rewritten
3. 03Our auditors have issued a “going concern” audit opinionNew
4. 04Recent volatility in capital markets may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness
5. 05respond to competitive pressures
6. 06Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights to our technologies or product candidates
7. 07Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our objectives relating to the discovery, development, regulatory approval and commercialization of our product candidates
8. 08attracting, hiring and retaining qualified personnel97% rewritten

Risks Related to the Discovery and Development of our Product Candidates

1. 09We are heavily dependent on the success of bel-sar, our only product candidate to date
2. 10If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for bel-sar, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired
3. 11the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
4. 12We have initiated but not yet completed a pivotal clinical trial nor have we commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects
5. 13If we fail to develop additional product candidates, or obtain additional indications of our first product candidate, our commercial opportunity could be limited
6. 14Bel-sar is a biologic that requires the use of multiple medical devices, which may result in additional regulatory risks
7. 15Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
8. 16If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
9. 17We are conducting a clinical trial outside the United States, and we may in the future conduct additional clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials
10. 18We plan to seek regulatory approval of our current or future product candidates outside of the United States. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction
11. 19The results of preclinical studies and early clinical trials may not be predictive of future results
12. 20Interim, “top-line,” and preliminary or early data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
13. 21our reputation may suffer
14. 22We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our product candidates
15. 23regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate
16. 24injunctions or the imposition of civil or criminal penalties
17. 25We may be unable to obtain ODD for additional indications, or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced
18. 26Accelerated approval by the FDA, even if granted for bel-sar or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval26% rewritten
19. 27scientific concerns regarding product safety or efficacy arise, the sponsor company fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by the sponsor in a request for the SPA change or are found to be false or omit relevant factsNew

Risks Related to Our Reliance on Third Parties

1. 28We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and expect to continue to do so, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing60% rewritten
2. 29termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us

Risks Related to Commercialization

1. 30If bel-sar or any future product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable64% rewritten
2. 31We cannot predict whether physicians, physicians’ organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatmentsNew
3. 32We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue
4. 33We may face competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do
5. 34Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business
6. 35If the market opportunity for bel-sar is smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially
7. 36Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
8. 37Current and future healthcare legislative reform measures may have a material adverse effect on our business and results of operations

Risks Related to Our Intellectual Property

1. 38Our ability to compete may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantage
2. 39any patents issued to us may be successfully challenged by third parties
3. 40We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
4. 41If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates
5. 42If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to bel-sar or a future product candidate, thereby potentially extending the term of marketing exclusivity for such product, our business may be harmed
6. 43Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position
7. 44We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection
8. 45If we or our licensors are unable to protect the confidentiality of the proprietary information related to our product or process, our business and competitive position would be harmed

Risks Related to our Business and Industry

1. 46If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to pursue our business strategy and continue as a going concern will be impaired, could result in loss of markets or market share and could make us less competitive21% rewritten
2. 47If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
3. 48Changes in tax laws or in their implementation or interpretation may adversely affect us or our investors
4. 49AI presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data90% rewritten
5. 50Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
6. 51Any future acquisitions, in-licensing or strategic partnerships may increase our capital requirements, dilute our stockholders, divert our management’s attention, cause us to incur debt or assume contingent liabilities and subject us to other risks
7. 52We or the third parties upon whom we depend on may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
8. 53We expect to significantly expand our organization, including building sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
9. 54Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any current or future product candidates that we may develop
10. 55the inability to commercialize any current or future product candidates that we may develop

Risks Related to Our Common Stock

1. 56If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
2. 57Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
3. 58Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited44% rewritten
4. 59Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
5. 60We may be subject to securities litigation, which is expensive and could divert management attention
6. 61Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
7. 62changes in general market and economic conditions, including inflationary pressures
8. 63Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
9. 64If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could harm our business
10. 65the authority of the Board to issue preferred stock on terms determined by the Board without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock
11. 66Future sales and issuances of our common stock or rights to acquire shares of our common stock, could result in additional dilution to the ownership of our stockholders and cause the market price of our common stock to decline significantly38% rewritten
12. 67termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements
13. 68Our employees, independent contractors, consultants, academic collaborators, partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
14. 69We are an “emerging growth company” and a “smaller reporting company” and we cannot be certain if the reduced reporting requirements applicable to “emerging growth companies” and “smaller reporting companies” will make our common stock less attractive to investors
15. 70The market price of our stock may be volatile, and you could lose all or part of your investment
16. 71general economic, industry, and market conditions, including inflationary pressures
17. 72We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives
18. 73Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
19. 74Global economic uncertainty and unfavorable global economic conditions caused by political instability, changes in trade agreements and conflicts, such as the Russia-Ukraine conflict and the conflict in the Middle East, could adversely affect our business, financial condition, results of operations or prospects23% rewritten